CARTESIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.03 USD | +0.62% |
|
+17.42% | +1.68% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 107 | 374.3 | - | - |
| Enterprise Value (EV) 1 | 107 | 147.7 | 54.25 | 180.8 |
| P/E ratio | -0.42 x | -13 x | -7.73 x | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 4.11 x | - | - | - |
| EV / Revenue | 4.11 x | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -7.07 x | -1.4 x | -3.66 x |
| FCF Yield | - | -14.1% | -71.7% | -27.3% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,173 | 17,796 | - | - |
| Reference price 2 | 20.68 | 21.03 | 21.03 | 21.03 |
| Announcement Date | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 26 | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -86.42 | -40.25 | -66.38 | -60 |
| Operating Margin | - | -332.32% | - | - | - |
| Earnings before Tax (EBT) 1 | -6.455 | -238.7 | -32.18 | -48.34 | - |
| Net income 1 | -6.455 | -219.7 | -37.84 | -64.67 | - |
| Net margin | - | -844.91% | - | - | - |
| EPS 2 | - | -49.80 | -1.615 | -2.720 | - |
| Free Cash Flow 1 | - | - | -20.88 | -38.88 | -49.32 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -8.625 | -9 | -10.38 | -12.25 | -14 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.289 | -7.616 | -8.46 | -9.814 | -10.94 |
| Net income 1 | -8.144 | -8.308 | -9.73 | -11.66 | -13.47 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.3500 | -0.3550 | -0.4150 | -0.4950 | -0.5700 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 227 | 320 | 194 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -20.9 | -38.9 | -49.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.03
USD
Average target price
56.25
USD
Spread / Average Target
+167.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.68% | 374M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RNAC Stock
- Financials Cartesian Therapeutics, Inc.
